Q3 FY2026 · ended Sep 30, 2026 · Revenue $3.10B, +10.0% YoY · Filed Oct 23, 2026
Quest Diagnostics Inc (DGX) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $3.1 billion and net income of $312.0 million. Free cash flow was $445.0 million. As of Sep 30, 2026 it held $797.0 million in cash and investments and $6.3 billion in total debt.
Revenue
$3.10B
+10.0% vs year-ago quarter
Net income
$312.00M
+27.3% vs year-ago quarter
Operating cash flow
$611.00M
+8.5% vs year-ago quarter
Free cash flow
$445.00M
+6.2% vs year-ago quarter
EPS
$2.78
+28.7% vs year-ago quarter
Dividend per share
$0.86
+7.5% vs year-ago quarter
Shares outstanding
110.02M
-1.1% vs year-ago quarter
Net cash
$-5.49B
Q3 FY2026
Operating margin
14.6%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- DGX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Secaucus, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1022079
- Former names
- CORNING CLINICAL LABORATORIES INC (until Mar 19, 1997)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $3.1B | $3.0B | $2.9B | $2.8B | $2.8B |
| Operating income | $479.0M | $459.0M | $399.0M | $386.0M | $386.0M |
| Net income | $312.0M | $320.0M | $252.0M | $245.0M | $245.0M |
| Diluted EPS | $2.78 | $2.84 | $2.24 | $2.17 | $2.16 |
| Operating cash flow | $611.0M | $597.0M | $278.0M | $465.0M | $563.0M |
| Free cash flow | $445.0M | $459.0M | $164.0M | $307.0M | $419.0M |
| Total assets | $17.2B | $16.9B | $16.7B | $16.2B | $16.2B |
| Stockholders' equity | $7.6B | $7.5B | $7.4B | $7.2B | $7.3B |
| Cash and investments | $797.0M | $626.0M | $393.0M | $420.0M | $432.0M |
| Total debt | $6.3B | $6.4B | $1.3B | $6.4B | $1.2B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 23, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 6, 2026 | Oct 6, 2026 |
| 10-Q | Quarterly report | Jul 23, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 23, 2026 | Jul 23, 2026 |
All 1005 Quest Diagnostics Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.